Results 81 to 90 of about 728 (161)

Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond [PDF]

, 2022
Olivotto, Iacopo
core   +1 more source

Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials [PDF]

Aims: Data on cardiac myosin inhibitors (CMIs) in obstructive hypertrophic cardiomyopathy (oHCM) are rapidly emerging. This systematic review and meta-analysis evaluated the efficacy and safety of CMIs in randomized placebo-controlled trials. Methods:
Coats, Caroline J., Goldie, Fraser C., Henderson, Alasdair D., Lee, Matthew M.Y., Masri, Ahmad, Olivotto, Iacopo   +5 more
core   +1 more source

Novel process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl) -2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide [PDF]

: The present invention relates to a novel process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, which is referred to as Aficamten and represented by the following structural
, Anonymous
core   +1 more source

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside [PDF]

, 2022
Coppini, Raffaele, Olivotto, Iacopo, Palandri, Chiara, Santini, Lorenzo   +3 more
core   +1 more source

In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor

Xenobiotica
Aficamten, a small molecule selective inhibitor of cardiac myosin, was characterised in preclinical in vitro and in vivo studies.Protein binding in human plasma was 10.4% unbound and ranged from 1.6% to 24.9% unbound across species. Blood-to-plasma ratios ranged from 0.69 to 1.14 across species.
Rajaa, Sukhun, Peadar, Cremin, Donghong, Xu, Jeanelle, Zamora, Jennifer, Cheung, Luke, Ashcraft, Mark P, Grillo, Bradley P, Morgan   +7 more
openaire   +2 more sources

INIBIDORES DE MIOSINA E CARDIOMIOPATIA HIPERTRÓFICA: UMA POSSÍVEL SOLUÇÃO PARA ATLETAS DE ALTO RENDIMENTO? [PDF]

INTRODUÇÃO: A cardiomiopatia hipertrófica (CMH) é uma doença cardíaca de origem genética caracterizada por hipertrofia ventricular esquerda, podendo apresentar formas assintomáticas até insuficiência cardíaca refratária.
Laranjeiras, Mel Rodrigues, Piedade, Marina Cleto Miarelli, Teixeira, João Victor Marques, Valadares, Lícia Campos   +3 more
core   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Incidence of Ventricular Arrhythmias and Sudden Cardiac Death with Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. [PDF]

J Pers Med
Katic J, Bulum T, Borovac JA.
europepmc   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. [PDF]

Drug Des Devel Ther
Hou L, Lin B, Ji X, Huang A.
europepmc   +1 more source

Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury [PDF]

Purpose: Reperfusion of the ischaemic heart is essential to limit myocardial infarction. However, reperfusion can cause cardiomyocyte hypercontracture.
Davidson, Sean M, Yellon, Derek M, Yusof, Nur Liyana Mohammed   +2 more
core